Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents

Biochemical Pharmacology

Volumn 64, Issue 12, 2002, Pages 1785-1791

  Pacher, Pál ^a,b   Cziráki, Attila ^c   Mabley, Jon G ^a   Liaudet, Lucas ^d,e   Papp, Lajos ^c   Szabó, Csaba ^a,b,d  

^a INOTEK CORPORATION   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cardiac collapse; Cardiac function; Endotoxin; Poly(ADP ribose) polymerase; Shock

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ESCHERICHIA COLI ENDOTOXIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVATION; ENZYME REPRESSION; GENE DELETION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEMODYNAMICS; KNOCKOUT MOUSE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RUGBY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

ANIMALS; DEATH; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENDOTOXINS; ENZYME ACTIVATION; GENE DELETION; HEART DISEASES; HEART FUNCTION TESTS; LIPOPOLYSACCHARIDES; MALE; MICE; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR;

EID: 0037114463     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01421-1     Document Type: Article

References (31)

1. Virag L., Szabó C. The therapeutic potential polymerase inhibitors. Pharmacol. Rev. 54:2002;375-429.
2. Thiemermann C., Bowes J., Myint F.P., Vane J.R. Inhibition of the activity of poly(ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 94:1997;679-683.
3. Zingarelli B., Salzman A.L., Szabó C. Genetic disruption of poly(ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res. 83:1998;85-94.
4. Szabó G., Bährle S., Stumpf N., Sonnenberg K., Szabó E., Pacher P., Csont T., Schulz R., Denger T.J., Liaudet L., Jagtap P.G., Southan G.J., Vahl C.F., Hagl S., Szabó C. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90:2002;100-106.
5. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Haskó G., Szabó C. Activation of poly(ADP-ribose) polymerase contributes to the development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300:2002;862-867.
6. Eliasson M.J., Sampei K., Mandir A.S., Hurn P.D., Traystman R.J., Bao J., Pieper A., Wang Z.Q., Dawson T.M., Snyder S.H., Dawson V.L. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 3:1997;1089-1095.
7. Burkart V., Wang Z.-Q., Radons J., Heller B., Herceg Z., Stingl L., Wagner E.F., Kolb H. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozotocin. Nat. Med. 5:1999;314-319.
8. Pieper A.A., Brat D.J., Krug D.K., Watkins C.C., Gupta A., Blackshaw S., Verma A., Wang Z.Q., Snyder S.H. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3059-3064.
9. Pacher P., Liaudet L., Soriano F.G., Mabley J.G., Szabó E., Szabó C. The role of poly(ADP-ribose) polymerase in the development of cardiovascular dysfunction in diabetes mellitus. Diabetes. 51:2002;514-521.
10. Soriano F.G., Virág L., Jagtap P., Szabó E., Mabley J.G., Liaudet L., Marton A., Hoyt D.G., Murthy K.G.K., Salzman A.L., Southan G.J., Szabó C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 7:2001;108-113.
11. Soriano F.G., Pacher P., Mabley J., Liaudet L., Szabó C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89:2001;684-691.
12. Szabó C., Cuzzocrea S., Zingarelli B., O'Connor M., Salzman A.L. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly(ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100:1997;723-725.
13. Oliver F.J., Ménissier-de Murcia J., Nacci C., Decker P., Andriantsitohaina R., Muller S., de la Rubia G., Stoclet J.C., de Murcia G. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 18:1999;4446-4454.
14. Kuhnle S., Nicotera P., Wendel A., Leist M. Prevention of endotoxin-induced lethality, but not of liver apoptosis in poly(ADP-ribose) polymerase-deficient mice. Biochem. Biophys. Res. Commun. 263:1999;433-438.
15. Liaudet L., Soriano F.G., Szabó E., Virág L., Mabley J.G., Salzman A.L., Szabó C. Protection against hemorrhagic shock in mice genetically deficient in poly-(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10203-10208.
16. Goldfarb R.D., Marton A., Szabó E., Virág L., Salzman A.L., Glock D., Akhter I., McCarthy R., Parrillo J.E., Szabó C. Protective effect of a novel, potent inhibitor of poly (adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit. Care Med. 30:2002;974-980.
17. Faro R., Toyoda Y., McCully J.D., Jagtap P., Virág L., Bianchi C., Levitsky S., Szabó C., Sellke F.W. Myocardial protection by PJ34, a novel potent poly(ADP-ribose) synthetase inhibitor. Ann. Thorac. Surg. 73:2002;575-581.
18. Liaudet L., Szabó E., Timashpolsky L., Virág L., Cziráki A., Szabó C. Suppression of poly(ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br. J. Pharmacol. 133:2001;1424-1430.
19. Soriano F.G., Liaudet L., Szabó E., Virág L., Mabley J.G., Pacher P., Szabó C. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock. 17:2002;286-292.
20. Jagtap P., Soriano F.G., Virág L., Liaudet L., Mabley J., Szabó E., Haskó G., Marton A., Lorigados C.B., Gallyas F. Jr., Sümegi B., Hoyt D.G., Baloglu E., VanDuzer J., Salzman A.L., Southan G.J., Szabó C. Novel phenanthridinone inhibitors of poly(adenosine 5(-diphosphate-ribose) synthetase: potent cytoprotective and anti-shock agents. Crit. Care. Med. 30:2002;1071-1082.
21. Mabley J.G., Jagtap P., Perretti M., Getting S.J., Salzman A.L., Virág L., Szabó E., Soriano F.G., Liaudet L., Abdekarim G.F., Haskó G., Marton A., Southan G.J., Szabó C. Anti-inflammatory effects of a novel potent inhibitor of poly(ADP-ribose) polymerase. Inflamm. Res. 50:2001;561-569.
22. Liaudet L., Pacher P., Mabley J.G., Virág L., Soriano F.G., Haskó G., Szabó C. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am. J. Respir. Crit. Care Med. 165:2002;372-377.
23. Grupp I.L., Jackson T.M., Hake P., Grupp G., Szabó C. Protection against hypoxia-reoxygenation in the absence of poly(ADP-ribose) synthetase in isolated working hearts. J. Mol. Cell. Cardiol. 31:1999;297-303.
24. Docherty J.C., Kuzio B., Silvester J.A., Bowes J., Thiemermann C. An inhibitor of poly(ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br. J. Pharmacol. 127:1999;1518-1524.
25. Zingarelli B., Szabó C., Salzman A.L. Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology. 116:1999;335-345.
26. Szabó C., Virág L., Cuzzocrea S., Scott G.S., Hake P., O'Connor M.P., Zingarelli B., Salzman A., Kun E. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3867-3872.
27. Hassa P.O., Hottiger M.O. A role of poly(ADP-ribose) polymerase in NF-κB transcriptional activation. Biol. Chem. 380:1999;953-959.
28. Hassa P.O., Covic M., Hasan S., Imhof R., Hottiger M.O. The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J. Biol. Chem. 276:2001;45588-45597.
29. Chang W.-J., Alvarez-Gonzalez R. The sequence-specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of poly(ADP-ribose) polymerase 1. J. Biol. Chem. 276:2001;47664-47670.
30. Haskó G., Mabley J.G., Németh Z.H., Pacher P., Deitch E.A., Szabó C. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol. Med. 8:2002;283-289.
31. Ha H.C., Hester L.D., Snyder S.H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. U.S.A. 99:2002;3270-3275.